Through its consulting services and solutions, Encore assists customers with a range of strategy, advisory, implementation, process-redesign, optimization, analytics and performance-improvement initiatives. Founded in 2009, Encore has more than 300 employees located throughout North America, including approximately 250 consultants. Its primary business is focused on implementation and advisory services around electronic health records (EHR).
Quintiles said the addition of these capabilities will enhance its EHR expertise, which is becoming increasingly important as biopharmaceutical customers, payers and providers focus on measuring outcomes based on real-world performance in terms of clinical effectiveness and value.
“Today’s announcement signifies the increasing importance of leveraging EHR and real-world information to inform our customers and improve their probability of success,” said Tom Pike, CEO of Quintiles. “Encore has significant EHR expertise, strong relationships with many large U.S. provider networks and academic medical centers, as well as experienced consultants, proven tools, and methodologies. It will be a key strategic addition for our business that will extend our services suite and allow us to work with Encore to strengthen its provider-focused solutions.”
Biopharmaceutical companies are increasingly interested in the “real-world” outcomes associated with their medicines to enable optimal market access. Quintiles said Encore’s expertise with hospitals and hospital information will help it extend its service offerings meaningfully for biopharmaceutical companies.
Encore will be able to leverage Quintiles’ capabilities and global scale to accelerate its vision of enhancing clinical outcomes through data-driven performance improvement. Additionally, Encore can utilize the expertise of Quintiles’ 950 medical doctors, 900 Ph.D.’s, nurse educators and world-class biostatisticians to help hospitals and providers solve their most pressing population health challenges.
“Today is the beginning of an exciting new chapter for Encore,” said Dana Sellers, chief executive officer, Encore. “Encore was founded with a focus on driving value through data to improve performance and clinical outcomes. I believe that this focus and our vision for the future align well with Quintiles. We will be joining a global leader, and we look forward to working together to help deliver further advancements in healthcare.”
The transaction, subject to standard and customary closing conditions, is expected to close later this quarter. Upon completion of this transaction, Encore will join Quintiles’ Integrated Healthcare Services segment and be known as “Encore, A Quintiles Company.”
Financial terms are not being disclosed. The acquisition is not expected to have a material impact on Quintiles’ 2014 earnings per share.